Company Overview and News
KUALA LUMPUR (Sept 12): The FBM KLCI dipped 0.55% at midday break today, in line with pull back at most regional markets.
4065 7036 7113 5681 TPGVF 0096 9334 6033 7277 7123 5199 TGLVY 5139 5238 PNADF 3026 0900 2836 HIPEF PNAGF 3719
KUALA LUMPUR (Sept 7): The FBM KLCI pared some of its gains at mid-morning today amid some chopping trading as regional markets slipped.
4065 7036 BATS 4162 0096 7087 5014 7123 4863 3867 5819 MYPRY MYTEF 2836 BSMAF GEBHF 3719 1818
PPB Group Bhd (Sept 5, RM16.88) Maintain neutral with a higher target price (TP) of RM17.63: PPB Group Bhd organised an analyst briefing on Tuesday and we returned feeling positive about the company’s long-term prospects. This is due to long-term stable earnings prospects seen from Wilmar International Ltd, improved earnings from PPB’s grains and agribusiness division and its superior balance sheet with net cash of RM684 million.
WLMIY WLMIF 4065 F34
KUALA LUMPUR (Sept 5): The FBM KLCI remained in the red at mid-morning and was down 0.52%, in line with the weaker regional markets.
HLFBF APEXF 7173 PBLOF 7090 4065 7036 1082 BATS 4162 0162 1295 8311 6033 PNADF 0104 2216 5819 PNAGF 3719
KUALA LUMPUR (Sept 4): PPB Group Bhd plans to roll out Phases 3 and 4 of Taman Tanah Aman in Seberang Jaya, Penang by end 2018. The phases comprise a total of 36 units of 3-storey bungalows.
KUALA LUMPUR: The FBM KLCI ended a volatile August on a firm note, with the market seeing the re-entry of foreign funds – but still not in a big way – since the May 9 General Election. For the month, the KLCI is up 1.75% or 31.3 points to end at 1,819.66. However, the 30-stock index is still way off the all-time closing high of 1,895 on April 19. At 5pm on Thursday, the KLCI was down 0.98 of a point to 1,819.
PBLOF BRDBF 4065 7113 4197 5681 TPGVF 1295 6033 5210 TGLVY PNADF SMEBF 5819 PNAGF
KUALA LUMPUR (Aug 29): Based on corporate announcements and news flow today, stocks in focus on Monday (Aug 30) may include Econpile Holdings Bhd, Destini Bhd, Sentoria Group Bhd, Dayang Enterprise Holdings Bhd, Telekom Malaysia Bhd, Bumi Armada Bhd, CIMB Group Holdings Bhd, Taliworks Corp Bhd, YTL Corp Bhd, Pos Malaysia Bhd, Genting Malaysia Bhd, UMW Holdings Bhd, PPB Group Bhd, Boustead Holdings Bhd and 7-Eleven Malaysia Holdings Bhd.
BSTHY WLMIF BRDBF GMALF 4065 5253 5141 6742 5213 2771 CIMDF 5210 4634 GMALY WLMIY 1023 4588 4863 4715 YTLPF MYTEF BSMAF F34 1818
KUALA LUMPUR (Aug 29): PPB Group Bhd, which is controlled by tycoon Robert Kuok, saw its net profit more than triple to RM304.47 million in the second quarter ended June 30, 2018 (2QFY18) from RM93.2 million a year ago, on higher profit contribution from its 18.5%-owned associate Wilmar International Ltd.
WLMIY WLMIF 4065 F34
KUALA LUMPUR: The FBM KLCI closed lower on Wednesday as funds took profit on Digi, Hartalega and IHH Healthcare amid a weaker broader market but stocks in focus were Bumi Armada , FGV Holdings and Supermax. At 5pm, the KLCI was down 6.26 points or 0.34% to 1,820.64. Turnover was 2.69 billion shares valued at RM2.63bil. Decliners beat advancers 629 to 355 while 337 counters were unchanged. Global stocks faltered on Wednesday as optimism over a US-Mexico trade deal faded with investors anxious about Canada’s acquiescence and eyeing a deadline for the next round of China-U.
PBLOF BRDBF 4065 4197 5681 1295 6033 5210 PNADF 5225 SMEBF 5819 Q0F IHHHF PNAGF
The FBM KLCI snapped a five-week gain last week as the market started to take profit. The index declined 1.2% in a week to 1,783.47 points last Friday, in line with global market performances. However, the index rebounded this week and closed at 1,798.11 points.
4065 MYPRY 5168 5014 7277 HRGHY
PPB Group Bhd (Aug 14, RM16.88) Maintain outperform with an unchanged target price of RM18.60: PPB Group Bhd’s associate, Wilmar International Ltd, recorded a first half of financial year 2018 (1HFY18) core net profit (CNP) of US$410 million (RM1.68 billion), which was broadly in line with expectations at 35% of the consensus’ US$1.16 billion forecast and our US$1.17 billion estimate. Historically, Wilmar’s earnings are stronger in 2H, accounting for 60% to 70% of full-year CNP.
WLMIY WLMIF 4065 F34
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...